PL2694101T3 - Kompozycje farmaceutyczne do profilaktyki i lub leczenia choroby HIV u ludzi - Google Patents

Kompozycje farmaceutyczne do profilaktyki i lub leczenia choroby HIV u ludzi

Info

Publication number
PL2694101T3
PL2694101T3 PL12721921T PL12721921T PL2694101T3 PL 2694101 T3 PL2694101 T3 PL 2694101T3 PL 12721921 T PL12721921 T PL 12721921T PL 12721921 T PL12721921 T PL 12721921T PL 2694101 T3 PL2694101 T3 PL 2694101T3
Authority
PL
Poland
Prior art keywords
humans
treating
preventing
pharmaceutical compositions
hiv disease
Prior art date
Application number
PL12721921T
Other languages
English (en)
Inventor
Jean-Marie Andrieu
Louis Lu
Original Assignee
Université Paris Descartes
Institut De Recherche Pour Le Développement (Ird)
Biovaxim Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46969619&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2694101(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Université Paris Descartes, Institut De Recherche Pour Le Développement (Ird), Biovaxim Limited filed Critical Université Paris Descartes
Publication of PL2694101T3 publication Critical patent/PL2694101T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL12721921T 2011-04-06 2012-04-06 Kompozycje farmaceutyczne do profilaktyki i lub leczenia choroby HIV u ludzi PL2694101T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2011/072481 2011-04-06
US201161534088P 2011-09-13 2011-09-13
CNPCT/CN2012/070761 2012-01-30
US201261609051P 2012-03-09 2012-03-09
EP12721921.0A EP2694101B1 (en) 2011-04-06 2012-04-06 Pharmaceutical compositions for preventing and/or treating an hiv disease in humans

Publications (1)

Publication Number Publication Date
PL2694101T3 true PL2694101T3 (pl) 2017-07-31

Family

ID=46969619

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12721921T PL2694101T3 (pl) 2011-04-06 2012-04-06 Kompozycje farmaceutyczne do profilaktyki i lub leczenia choroby HIV u ludzi

Country Status (20)

Country Link
US (1) US9839684B2 (pl)
EP (3) EP3173096A1 (pl)
JP (1) JP6054370B2 (pl)
KR (1) KR101814857B1 (pl)
CN (1) CN105709221B (pl)
AP (1) AP2013007166A0 (pl)
AU (1) AU2012238351B2 (pl)
BR (1) BR112013025481B8 (pl)
CA (1) CA2832022C (pl)
CL (1) CL2013002836A1 (pl)
DK (1) DK2694101T3 (pl)
ES (1) ES2606511T3 (pl)
IL (1) IL228666A (pl)
MX (1) MX343037B (pl)
PH (1) PH12013502064A1 (pl)
PL (1) PL2694101T3 (pl)
PT (1) PT2694101T (pl)
RU (1) RU2609769C2 (pl)
SG (1) SG194079A1 (pl)
WO (1) WO2012137071A2 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1397155T3 (en) * 2001-06-21 2015-12-07 Genentech Inc Prolonged release formulation
JO3753B1 (ar) 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه
US10857223B2 (en) * 2014-06-10 2020-12-08 Case Western Reserve University Autologous and allogenic HIV-1 proteins for the treatment of latent HIV-1 infection
DK3254693T3 (da) * 2015-01-30 2021-06-14 Univ Tokyo Mælkesyrebakterieindeholdende sammensætning, oral farmaceutisk sammensætning til at behandle hpv-infektion og/eller hpv-associerede tumorer og slimhindeimmunitietsinducerende middel
WO2020188111A1 (en) * 2019-03-21 2020-09-24 21C Bio Vaccine to pathogenic immune activation cells during infections
US11077185B2 (en) 2019-03-21 2021-08-03 21C Bio Vaccine to pathogenic immune activation cells during infections
EP4088729B1 (en) 2020-01-10 2025-11-12 Immunobiome Inc. Novel lactobacillus plantarum strain, polysaccharides derived from strain, and use thereof
EP4288091A4 (en) * 2021-02-02 2025-07-02 Provaxus Inc NOVEL IMMUNOMODULATION PLATFORM AND METHODS OF USE

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL82104A0 (en) 1986-04-08 1987-10-30 Usa Recombinant vaccinia virus expressing human retrovirus genes and method for producing htlb-iii envelope proteins
JPS6485072A (en) 1987-09-25 1989-03-30 Nat Inst Health Recombinant vaccinia virus
JPH01148183A (ja) 1987-12-04 1989-06-09 Hiroshi Shibuta 組み換えワクチニアウイルス
JP3140757B2 (ja) 1989-02-06 2001-03-05 デイナ・フアーバー・キヤンサー・インステイテユート パッケージング欠陥ｈｉｖプロウイルス、細胞系及びその使用
GB8923123D0 (en) 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
US5861282A (en) 1989-10-16 1999-01-19 Whitehead Institute For Biomedical Research Non-infectious HIV particles and uses therefor
CA2068713A1 (en) 1989-11-20 1991-05-21 Omar K. Haffar Non-replicating recombinant-made retroviral particles used as antiviral agents and immunogens
ATE183235T1 (de) 1990-03-21 1999-08-15 Wolf Hans Joachim Prof Dr Für abgeänderte retrovirale gag-polypeptide kodierende dna-sequenzen und diese enthaltende impfstoffe oder aggregate davon
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
JP3602530B2 (ja) 1991-03-07 2004-12-15 ヴァイロジェネティクス コーポレイション 遺伝子操作したワクチン菌株
US5766598A (en) 1991-03-07 1998-06-16 Virogenetics Corporation Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products
CA2110489A1 (en) 1991-06-14 1992-12-23 Enzo Paoletti Immunodeficiency virus recombinant poxvirus vaccine
EP1380651A2 (en) 1991-08-26 2004-01-14 Baxter Healthcare S.A. Recombinant fowlpox virus with intact FPV-tk-gene
DE4141741A1 (de) 1991-12-13 1993-06-17 Gisela Kielmann Verfahren zur bekaempfung des human imune deficiency virus
US6511845B1 (en) 1992-08-07 2003-01-28 Alan R. Davis Methods for producing an immune response against HIV-1
US6136318A (en) 1993-02-26 2000-10-24 Cochran; Mark D. Recombinant fowlpox viruses and uses thereof
JPH07170982A (ja) 1993-09-09 1995-07-11 Nisshin Oil Mills Ltd:The ワクチンおよびその製造方法
WO1995007099A1 (en) 1993-09-09 1995-03-16 The Nisshin Oil Mills, Ltd. Vaccine and process for producing the same
US6080408A (en) 1994-08-22 2000-06-27 Connaught Laboratories Limited Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles
WO1996011708A1 (en) 1994-10-18 1996-04-25 Board Of Regents, The University Of Texas System Membrane expression of heterologous genes
WO1996040880A1 (en) 1995-06-07 1996-12-19 Syntro Corporation Recombinant fowlpox viruses and uses thereof
US5741492A (en) 1996-01-23 1998-04-21 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
JPH1085072A (ja) 1996-09-13 1998-04-07 Kichinosuke Takemaru 家具転倒防止器具
US6001155A (en) 1997-03-17 1999-12-14 Pease; John R. Polyphasic pressurized homogenizer
HRP980143A2 (en) * 1997-04-09 1999-02-28 Soo Sung Ko 4,4-disubstituted-3,4-dihydro-2 (1h)-quinazolinones useful as hiv reverse transcriptase inhibitors
US5895758A (en) * 1997-06-10 1999-04-20 Bio-Energy Systems Strain of lactobacillus Plantarum
EP0991767A1 (en) 1997-06-11 2000-04-12 Institut Pasteur Attenuated recombinant mycobacteria useful as immunogens or as vaccine components
JP3899165B2 (ja) 1997-08-06 2007-03-28 ビー・エル・オートテック株式会社 ロボットアームの過負荷保護装置
US6716823B1 (en) 1997-08-13 2004-04-06 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom, and uses thereof
US6121021A (en) 1997-12-16 2000-09-19 Connaught Laboratories Limited Constitutive expression of non-infectious HIV-like particles
US7189402B1 (en) 1998-02-06 2007-03-13 Research Development Foundation Live vaccine for human immunodeficiency virus
US6828460B2 (en) 1999-03-22 2004-12-07 Pfizer Inc. Resorcinol derivatives
US20040009936A1 (en) 1999-05-03 2004-01-15 Tang De-Chu C. Vaccine and drug delivery by topical application of vectors and vector extracts
WO2001002607A1 (en) 1999-07-06 2001-01-11 Merck & Co., Inc. Adenovirus carrying gag gene hiv vaccine
EP1084709A1 (en) 1999-09-17 2001-03-21 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Oral recombinant lactobacilli vaccines
WO2001031046A1 (en) 1999-10-26 2001-05-03 International Aids Vaccine Initiative Invasive bacterial vectors for expressing alphavirus replicons
WO2002072754A2 (en) 2001-03-08 2002-09-19 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mva expressing modified hiv envelope, gag, and pol genes
US20040105871A1 (en) 2000-03-02 2004-06-03 Robinson Harriet L. Compositions and methods for generating an immune response
US6544780B1 (en) 2000-06-02 2003-04-08 Genphar, Inc. Adenovirus vector with multiple expression cassettes
US20020155127A1 (en) 2000-06-02 2002-10-24 Danher Wang Genetic vaccine against human immunodeficiency virus
EP1320621A4 (en) 2000-09-15 2005-11-23 Merck & Co Inc IMPROVED ADENOVIRAL VACCINES OF THE FIRST GENERATION FOR THE EXPRESSION OF CODON-OPTIMIZED HIV-1 GAG, POL, NEF AND MODIFICATIONS (25.03.02)
US6733993B2 (en) 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
US20040101957A1 (en) 2001-09-14 2004-05-27 Emini Emilio A. Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol.nef and modifications
WO2002031168A2 (en) 2000-10-10 2002-04-18 Genstar Therapeutics Minimal adenoviral vector and recombinant vaccines based thereon
GB0030857D0 (en) 2000-12-18 2001-01-31 Medical Res Council Therapeutic compositions
KR20020059856A (ko) 2001-01-08 2002-07-16 김철중 에이치아이브이 유사입자의 제조
WO2002102409A1 (en) 2001-06-19 2002-12-27 Medical Research Council Inactivated mycobacterial ompatb and uses thereof
WO2003020893A2 (en) 2001-08-30 2003-03-13 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services New adenovirus type 7 vectors
US20070077257A1 (en) 2001-09-14 2007-04-05 Emini Emilio A Enhanced first generation adenovirus vaccines expressing condon optimized HIV1-Gag, Pol, Nef and modifications
CN1612753A (zh) 2001-11-14 2005-05-04 诺瓦瓦克斯有限公司 分枝杆菌疫苗
WO2003050238A2 (en) 2001-12-11 2003-06-19 University Of Iowa Research Foundation Receptor-targeted adenoviral vectors
CN1646020A (zh) 2002-01-31 2005-07-27 圣必健公司 将核酸和/或蛋白质导入呼吸系统的方法与制剂
US20040009937A1 (en) 2002-01-31 2004-01-15 Wei Chen Methods and composition for delivering nucleic acids and/or proteins to the respiratory system
EP1499736B1 (en) 2002-04-26 2009-03-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Improved chimeric glycoproteins and pseudotyped lentiviral vectors
JP2003321391A (ja) 2002-04-30 2003-11-11 Japan Science & Technology Corp 組換えワクシニアウイルスを用いたｈｉｖワクチン
DE10221411B4 (de) 2002-05-14 2004-07-08 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Rekombinantes Fowlpox-Virus
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
CA2487895A1 (en) * 2002-05-31 2003-12-11 Ciphergen Biosystems, Inc. Defensins: use as antiviral agents
CN1490056A (zh) 2002-10-18 2004-04-21 ��¡���ɵ°��̲��о����� 针对hiv-1的免疫方法和组合物
EP2363143A3 (en) 2003-03-28 2012-02-15 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services MVA expressing modified hiv envelope, gag, and pol genes
JP2007518460A (ja) 2003-05-09 2007-07-12 イントラヴァック インコーポレーテッド 皮内、皮下及び筋肉内注射用の無針注射器及びアンプル
US20100189747A1 (en) 2003-07-31 2010-07-29 Raymond Weinstein Compositions and methods for treating or preventing hiv infection
CN101291691A (zh) * 2003-08-28 2008-10-22 免疫反应公司 免疫原性hiv组合物和相关方法
JP2007037402A (ja) 2003-11-28 2007-02-15 Primmune:Kk 抗ヒト免疫不全ウイルス感染防御用キメラ５型／３５型アデノウイルスベクター
WO2005111205A1 (en) 2004-05-18 2005-11-24 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Tuberculosis vaccine
WO2005121378A2 (en) * 2004-06-03 2005-12-22 Saint Louis University Methods and compositions for vaccination
US7488828B2 (en) 2004-06-25 2009-02-10 Dow Agrosciences Llc Process for the preparation of 4-trifluoromethyl-2(1H)-pyridinone
EP2319860A3 (en) 2004-08-27 2011-06-15 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Recombinant MVA viruses expressing clade A/G, clade B, and clade C modified HIV env, gag and pol genes
EP1797175B1 (en) * 2004-10-04 2008-07-16 Biovaxim Limited Subtype-matched inactivated whole virus vaccines for treating patients with hiv infection
CA2853335A1 (en) * 2005-02-24 2006-11-23 Medical Research Council Hivcon: an hiv immunogen and uses thereof
BRPI0608798A2 (pt) 2005-05-12 2011-03-15 Glaxo Group Ltd vetor de adenovìrus, composição imunogênica, uso de um vetor de adenovìrus, método para preparar um vetor, uso de um vetor de vìrus e um carreador ou adjuvante farmaceuticamente aceitável, e, proteìna de fusão
EP1723965A1 (en) 2005-05-18 2006-11-22 Stallergenes Sa Compositions for antigen-specific induction of immuno-tolerance via oral immunization
WO2007140613A1 (en) 2006-06-06 2007-12-13 Mcgill University Fermented milk product and use thereof
DK2144626T3 (en) 2007-04-12 2015-02-09 Mico Bio Inc Tuberculosis vaccine and method of using same
WO2009093900A1 (en) 2008-01-25 2009-07-30 Stichting Top Institute Food And Nutrition Mid-log phase lactic acid bacteria for inducing immune tolerance in a subject

Also Published As

Publication number Publication date
AU2012238351A1 (en) 2013-10-24
PH12013502064A1 (en) 2019-07-03
DK2694101T3 (en) 2017-01-09
PT2694101T (pt) 2016-12-19
AU2012238351B2 (en) 2016-11-24
EP3173096A1 (en) 2017-05-31
CL2013002836A1 (es) 2014-07-25
ES2606511T3 (es) 2017-03-24
KR101814857B1 (ko) 2018-01-04
AP2013007166A0 (en) 2013-10-31
RU2013147745A (ru) 2015-05-20
IL228666A (en) 2017-12-31
CA2832022C (en) 2019-01-08
JP6054370B2 (ja) 2016-12-27
WO2012137071A2 (en) 2012-10-11
IL228666A0 (en) 2013-12-31
CA2832022A1 (en) 2012-11-10
CN105709221B (zh) 2020-11-17
BR112013025481A2 (pt) 2018-12-11
SG194079A1 (en) 2013-11-29
RU2609769C2 (ru) 2017-02-02
US9839684B2 (en) 2017-12-12
MX343037B (es) 2016-10-20
MX2013011540A (es) 2014-04-16
BR112013025481B8 (pt) 2022-11-08
JP2014511856A (ja) 2014-05-19
EP3000476A1 (en) 2016-03-30
EP2694101B1 (en) 2016-09-14
US20140302089A1 (en) 2014-10-09
KR20140042800A (ko) 2014-04-07
EP2694101A2 (en) 2014-02-12
NZ616283A (en) 2014-10-31
BR112013025481B1 (pt) 2020-06-23
CN105709221A (zh) 2016-06-29
WO2012137071A3 (en) 2012-11-29

Similar Documents

Publication Publication Date Title
IL231536A (en) Indazole-3-carboxamides, pharmaceuticals containing them and their use in the treatment of diseases
PT2740793T (pt) Composição de fármacos para o tratamento e/ou a prevenção de cancro
PL2672966T3 (pl) Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania
PL2740795T3 (pl) Kompozycja lekowa do leczenia nowotworu i/lub zapobiegania nowotworowi
PL2740798T3 (pl) Kompozycja leku do leczenia i/lub zapobiegania nowotworom
IL235923A0 (en) Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical preparations thereof
PT2729151T (pt) Composição farmacêutica, métodos de tratamento e suas utilizações
BR112012018947A2 (pt) composição farmacêutica para tratamento e\ou prevenção do cancêr
IL225597A0 (en) Pharmaceutical preparation, methods of treatment and its uses
IL236024A (en) The history of benzimidazole-proline and its pharmaceutical preparations
IL224545A (en) Combined Pharmaceuticals for the Treatment and Prevention of Infectious Diseases
IL252566B (en) Pharmacy preparations and methods
IL228666A (en) Pharmaceuticals for the prevention and / or treatment of HIV in humans
IL230957A0 (en) Pharmacy methods and preparations for the treatment of an eye disease in a patient
ITTO20110641A1 (it) Composizioni farmaceutiche e metodi di trattamento
IL236057B (en) History of 4,2,1-triazine-6-carboxamide and pharmaceutical preparations containing them
GB2497453B8 (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
IL228705A (en) Derivatives of Reliable Phenoxy-Ethyl, Pharmaceutical Preparations Containing and Using Them
SG11201400976WA (en) Methods and pharmaceutical compositions for treating cancer
IL221087A (en) Pharmacy or nutritional composition
EP2785335B8 (en) Methods and pharmaceutical compositions for the treatment of darier disease
GB201208315D0 (en) Pharmaceutical methods and compositions
ZA201307390B (en) Pharmaceutical compositions for preventing and/or treating an hiv disease in humans
PT3539540T (pt) Inibidor de sglt2 1-cloro-4-(beta-d-glucopiranos-1-il)-2-[4-((s)-tetra-hidrofurano-3-iloxi)-benzil]-benzeno em combinação com insulina para utilização num método para redução do risco de hipoglicemia